DepoMed, Inc. (NASDAQ:DEPO)
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Recs
Now that the Serada overhang has been removed, Depomed has a good shot at a rebound if Gralise and Glumetza revenues continue to show growth when Q1 earnings are released next month. The quarterly burn has also improved substantially and the lowest the stock has been since the approval of Gralise is 4.27.
Recs
High vOLUME bREAK OUT 1/31/13
Recs
PEG, P/FCF, analyst, EPS next 5 years.
Recs
Hurt bt abt. But graise launch 150m in cash
Recs
us pharma
Recs
DepoMed exhibits revenue growth at a low valuation.
Recs
MFI Screen
Recs
Magic Formula. Insider buying. Plenty of cash and proven ability to bring in money through partnering.
Recs
Gralise should be able to compete with generics. ER tech should pay dividends down the road.
Recs
This company has several meds in the pipeline. One just got approval(Gralise) and the other med is about to have word on approval for another med(Sereda). It also has a few other meds in the pipeline that are a year away or so. The only thing holding this stock from going to $15 - $20 a share is its contract dispute with Abbott. When that works itself out look for a nice rise in the stock price.
Recs
DepoMed’s DM-1796 will be FDA approved by or before the end of the month.
Recs
Proven technology, great pipeline, self financing and 2 potential Billion $ products. Just hope the company doesn't get bought in the next few years.
Recs
I like the number and type of products Depomed has in the pipeline. Also the relationships they have with major Pharma. Possible takeover within two years.
Recs
When all the bad news is out and the stock has oversold below $2.50, that's when I bought with real money and expect in 5 years to be more than a 5 bagger.
Just about perfect trade!
Recs
Great pipeline potential.<br />Cash flow positive wi 18-24 months.<br />Huge earnings potential.
Recs
"Cancer risk" can't see this being a good investment for the next few months at least.
http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix
Recs
I have been involved with this stock for awhile now and it has continued to increase in value slowly. the pace over the last week has quickened and I look for it to continue. Sales continue to rise and new products are being developed and licensed. I am begining to look at this company as a buy out caindidate for one of the big pharco's
Recs
magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008
Recs
It's Depo-tastic!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 33 : 1 2 Next »